In this webinar, leaders from cancer centers and biopharma companies will discuss the operational and institutional hurdles sites face and what can be done to address them. The panel will explore practical strategies to reduce burden, improve collaboration, and create a better experience for research staff and patients alike.
Join experts from Johnson & Johnson Innovative Medicine, Bayer, The START Center for Cancer Care, and Advarra to discuss the ethical use of real-world data in clinical research.
Clinical research drives medical progress. Advarra ensures participant safety and ethical standards through expert IRB oversight for life-changing therapies.
Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential As part of Oncology Research Pulse, our new thought leadership
Launched in January 2025, the Association of Multisite Research Corporations (AMRC) was set up by its founding members to advance
Our webinar discusses key near-term trends and regulations and investigate persistent challenges frequently throwing even the most efficient teams off track. Advarra and industry representatives will dive deeper into achieving critical milestones across study startup, conduct, and close out that every project manager should optimize.
At a busy research site, a clinical trial is ready to launch — but it’s stuck in limbo over a
Balancing Innovation, Ethics, and Operational Excellence in Adaptive Oncology Trials Clinical trials are evolving to incorporate adaptive designs, offering flexibility
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Solutions For Study Startup Study startup in a clinical trial is a critical stage to get your study up and
Selecting an electronic institutional review board (eIRB) system is a critical decision for institutions looking to streamline their research compliance
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
